UCB inks $1.6B global partnership with Novartis on Parkinson's disease

2 December 2021

Shares of Belgium’s largest drugmaker UCB (Euronext Brussels: UCB) were barely changed today, after it announced a global co-development and co-commercialization agreement with Swiss pharma giant Novartis (NOVN: VX) covering drug candidate UCB0599, that could earn the company over $1.6 billion.

UCB0599 is a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase II clinical development, and upon completion of the ongoing Phase I program, an opt-in for Novartis to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson’s disease (PD).

This is a new step for Novartis, which is not known for novel activity in the central nervous system (CNS) therapy sector.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK